Category: Evidence Explainers
Plain-English guides to study quality, statistics, evidence hierarchies and scientific uncertainty.
Amylin vs GLP-1: CagriSema and Emerging Obesity Drugs
Understand how amylin and GLP-1 targets differ, what CagriSema combines, and what published cagrilintide, petrelintide and eloralintide trials show.
Read analysis →Mass Spectrometry vs Amino Acid Analysis: What Peptide Tests Show
A primary-source comparison of mass spectrometry and amino acid analysis, separating peptide identity, sequence, composition and quantitative content.
Read analysis →What Is GLP-1? The Hormone, Receptor and Medicines Explained
A source-linked explanation of GLP-1 biology, the difference between a hormone and receptor agonist, and how to interpret single, dual and triple receptor claims.
Read analysis →Obesity Drug Clinical Trial Results Tracker (2026)
A continuously updated, source-linked tracker of major 2026 obesity-drug trial results, including retatrutide, CagriSema, survodutide and petrelintide.
Read analysis →Mounjaro and Eye Disorders in Australia: NAION Warning Explained (2026)
Australian evidence guide to Mounjaro, tirzepatide and NAION: what the TGA warning says, what 10 reports can and cannot establish, and why semaglutide evidence differs.
Read analysis →Compounded GLP-1 Australia (2026): What the TGA Rules Actually Say
Current Australian answer (checked 7 October 2026): Australian pharmacists must not compound medicines containing GLP-1 receptor agonist analogues. The prohibition took effect on 1 October 2024.…
Read analysis →GLP-1 Safety Warnings Australia (2026): TGA Updates Explained
Source-checked 7 October 2026: Australia’s TGA has updated warnings for GLP-1 receptor agonists and the dual GIP/GLP-1 medicine tirzepatide across several distinct issues: aspiration around general…
Read analysis →How to Read a Weight-Loss Drug Trial: Endpoints, Dropouts, Safety and Comparisons
An evidence-literacy guide to weight-loss drug trials: populations, endpoints, estimands, missing data, discontinuations, safety and cross-trial comparisons.
Read analysis →TB-500 Australia: Schedule 4, Human Evidence, FDA Review and WADA Rules
What TB-500 is, how it differs from full-length thymosin beta-4, what Australian Schedule 4 status means, and why human healing claims remain uncertain.
Read analysis →CJC-1295 and Ipamorelin: Evidence, FDA Safety Flags and 2026 WADA Status
CJC-1295 and ipamorelin are often marketed together, but they are different growth-hormone-pathway substances with limited clinical evidence and distinct safety questions.
Read analysis →